Blog
RSS FeedPosted by Michael Wonder on 01 Jul 2017
Public Summary Documents - March 2017 PBAC meeting
30 June 2017 - The public summary documents from the March 2017 PBAC meeting are now available. ...
Posted by Michael Wonder on 28 Jun 2017
ICER evidence report on abuse deterrent opioids finds limited evidence to demonstrate real world impact on opioid abuse
28 June 2017 - With substantially higher costs for abuse-deterrent formulations, and uncertainty regarding their impact on abuse, diversion, and switching ...
Posted by Michael Wonder on 27 Jun 2017
Guild caned on pharmacy review ban
27 June 2017 - The Pharmacy Guild of Australia has been criticised over attempts to boycott an independent review of ...
Posted by Michael Wonder on 27 Jun 2017
Interim report ‘a step backwards’
27 June 2017 - Peak bodies have come together to highlight potential problems with King Review suggestions. ...
Posted by Michael Wonder on 26 Jun 2017
‘Overcharging’ claims give false impression
26 June 2017 - Guild condemns PBS price fixing suggestion as article accuses pharmacies of overcharging. ...
Posted by Michael Wonder on 22 Jun 2017
Release of the review's interim report
22 June 2017 - The Review is pleased to present the interim report for the Review of Pharmacy Remuneration and ...
Posted by Michael Wonder on 29 May 2017
Draft report for the post-market review of COPD medicines
29 May 2017 - The draft report for the post-market review of chronic obstructive pulmonary disease medicines is available for ...
Posted by Michael Wonder on 19 May 2017
Post-market review of ezetimibe – notice of public consultation
19 May 2017 - The public consultation on the revised draft ezetimibe post-market review report to the PBAC will open ...
Posted by Michael Wonder on 13 May 2017
Institute for Clinical and Economic Review releases revised evidence report on dupilumab and crisaborole for treatment of atopic dermatitis
12 May 2017 - Limitations noted on the evidence for crisaborole; analyses find stronger evidence for dupilumab and suggest its price ...
Posted by Michael Wonder on 07 May 2017
Institute for Clinical and Economic Review's draft evidence report on abuse-deterrent opioids evaluates clinical and economic evidence on nine formulations
5 May 2017 - Public comment period now open until 2 June; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 26 Apr 2017
EMA publishes withdrawal assessment report for Graspa
25 April 2017 - On 14 November 2016, Erytech Pharma officially notified the CHMP that it wishes to withdraw its application ...
Posted by Michael Wonder on 24 Mar 2017
ICER releases draft evidence report on crisaborole and dupilumab for atopic dermatitis
24 March 2017 - Public comment period open until 21 April. ...
Posted by Michael Wonder on 11 Mar 2017
Institute for Clinical and Economic Review releases revised report on targeted immune modulators for treatment of rheumatoid arthritis
10 March 2017 - Analyses of evidence on comparative effectiveness raise questions about current step therapy protocols, while net prices for ...
Posted by Michael Wonder on 06 Mar 2017
ICER's final report on disease-modifying therapies for multiple sclerosis finds most drugs are over-priced in relation to benefits for patients; highlights need for stakeholder collaboration to address system issues
6 March 2017 - Key policy recommendations call on manufacturers to cease price increases and payers to ease coverage restrictions and ...
Posted by Michael Wonder on 04 Mar 2017
Public Summary Documents - PBAC November 2016 meeting
3 March 2017 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the PBAC November 2016 ...